Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 26 von 135

Details

Autor(en) / Beteiligte
Titel
Histologic Subtype of Metastatic Renal Cell Carcinoma Predicts Response to Combined Immunochemotherapy with Interleukin 2, Interferon α and 5-Fluorouracil
Ist Teil von
  • European urology, 2007-06, Vol.51 (6), p.1625-1632
Ort / Verlag
Switzerland: Elsevier B.V
Erscheinungsjahr
2007
Quelle
MEDLINE
Beschreibungen/Notizen
  • Abstract Objectives Combined immunochemotherapy with interleukin 2 (IL-2), interferon α (IFN-α), and 5-fluorouracil (5-FU) is an established first-line therapy for metastatic renal cell carcinoma (RCC). However, data on histologic parameters predictive of clinical benefit are rare. In this study, we evaluated the response to immunochemotherapy in the main histologic subtypes of renal cell carcinoma and performed a subgroup analysis of inoperable patients. Methods From 164 patients treated with one or two cycles of combined immunochemotherapy, radical nephrectomy had revealed 22 cases of papillary RCC (pRCC; 13.4%) and 131 cases of clear cell RCC (ccRCC; 79.9%). In the remaining 11 (6.7%) their disease was inoperable. The overall response rates were evaluated according to World Health Organization criteria. Results For ccRCC and inoperable disease, responses of 34.4% and 27.3% after one cycle and 28.8% and 16.7% after two cycles, respectively, were noted. In contrast, no patient with pRCC showed any response after two cycles of combined immunochemotherapy. Conclusions No objective response was seen in patients with pRCC. Hence, the use of immunotherapeutic agents must be questioned in this histologic subtype.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX